Angulin-1/LSR inhibition transiently disrupts the blood-tumor barrier to enhance doxil permeability and impair malignant glioma progression
Dominique T. Ferguson, Minhye Kwak, Sanghee Lim, Melissa Cesaire, Jatia Mills, Mahalia Dalmage, Jane Jones, Sergey G. Tarasov, Marzena Dyba, Robert W. Robey, Yanbo Yang, Shae K. Simpson, Baktiar O. Karim, Donna O. Butcher, Robyn D. Gartrell, , Sadhana Jackson
The paper investigates how Angubindin-1 disrupts the blood-tumor barrier by targeting Angulin-1/LSR, enhancing drug permeability and reducing glioma progression.
bioRxiv · Jul 31, 2025 · PreprintCell Biology